Richard Nathan

Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection

Mark H. Wilcox, Dale N. Gerding, Ian R. Poxton et al. · New England Journal of Medicine · 2017 · 832 citations · Full text

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

Carlos A. DiazGranados, Andrew J. Dunning, Murray Kimmel et al. · New England Journal of Medicine · 2014 · 820 citations · Full text

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

Richard Vickers, Glenn Tillotson, Richard Nathan et al. · The Lancet Infectious Diseases · 2017 · 115 citations · Full text

Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial

Guy de Bruyn, Jamshid Saleh, David Workman et al. · Vaccine · 2016 · 95 citations · Full text

Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II)

Mark Wilcox, Dale N. Gerding, Ian R. Poxton et al. · Open Forum Infectious Diseases · 2015 · 18 citations · Full text

Immunology, Care Antibiotics, Pharmacotherapy +18